Radiation therapy firm Accuray said that a five-year outcomes study has demonstrated long-term efficacy of its CyberKnife robotic radiosurgery system in low-risk prostate cancer patients.
Published in the January 10 issue of Radiation Oncology, the multicenter study found that 93% of patients had no recurrence of their cancer at a median follow-up of five years. That rate compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy, according to the Sunnyvale, CA-based firm.
Related Reading
Accuray moves to new Nasdaq market, January 3, 2011
Accuray creates medical affairs unit, December 20, 2010
Accuray gets FDA nod for CyberKnife tool, December 15, 2010
Accuray revenues slump in Q1, November 9, 2010
Accuray expands CyberKnife service program, October 29, 2010
Copyright © 2011 AuntMinnie.com
